$12.40
3.13% day before yesterday
Nasdaq, Sep 05, 10:14 pm CET
ISIN
US21900C3088
Symbol
CRMD

CorMedix Inc Stock News

Neutral
GlobeNewsWire
5 days ago
- Transformational deal for CorMedix that expands and diversifies company's commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue growth potential -
Neutral
GlobeNewsWire
10 days ago
BERKELEY HEIGHTS, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be presenting and participating in investor meetings at upcoming investor conferences taking place in September.
Positive
Seeking Alpha
13 days ago
CorMedix has achieved GAAP profitability after years of losses, with the market yet to fully price in this turnaround. Shares trade at a moderate 17x forward P/E, but with a projected 8x forward P/E, I see further upside potential. DefenCath's FDA approval and successful commercialization underpin CorMedix's financial strength and independence from larger biotech partners.
Neutral
Seeking Alpha
about one month ago
CorMedix, Inc. (NASDAQ:CRMD ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Joseph Todisco - CEO & Director Matthew T. David - Executive VP & CFO Conference Call Participants Anish Nikhanj - RBC Capital Markets, Research Division Brandon Richard Folkes - H.C.
Positive
WSJ
about one month ago
The buyer said the deal adds six marketed infectious-disease products to its offerings.
Neutral
Business Wire
about one month ago
PARSIPPANY, N.J.--(BUSINESS WIRE)--Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring its Portfolio Value and Industry Leadership.
Neutral
GlobeNewsWire
about one month ago
‒ Q2 2025 Net Revenue of $39.7mm; Net Income of $19.8mm; Adjusted EBITDA of $22.4mm ‒ ‒ Company Announces Acquisition of Melinta Therapeutics ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J.
Neutral
GlobeNewsWire
about one month ago
Transformational deal for CorMedix that expands and diversifies company's commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue growth potential Transaction expected to be near-term accretive to EPS with double-digit accretion expected in 2026; annual run-rate synergies expected to be ~$35 to $45 million Pro forma 2025 combi...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today